A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Dapa-CKD
2 other identifiers
interventional
4,304
21 countries
390
Brief Summary
The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Feb 2017
Typical duration for phase_3
390 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 26, 2017
CompletedFirst Posted
Study publicly available on registry
January 30, 2017
CompletedStudy Start
First participant enrolled
February 2, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 12, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 12, 2020
CompletedResults Posted
Study results publicly available
July 7, 2021
CompletedJuly 7, 2021
June 1, 2021
3.4 years
January 26, 2017
April 19, 2021
June 15, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.
End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
Up to 38.2 months
Secondary Outcomes (3)
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or Renal Death.
Up to 38.2 months
Time to the First Occurrence of Either of the Components of the Composite: CV Death or Hospitalization for Heart Failure.
Up to 38.2 months
Time to Death From Any Cause.
Up to 38.2 months
Study Arms (2)
Dapagliflozin
EXPERIMENTALPatients will be randomized 1:1 to either dapagliflozin or placebo.
Placebo
PLACEBO COMPARATORPlacebo matching dapagliflozin.
Interventions
10 mg or 5 mg tablets given once daily, per oral use.
Eligibility Criteria
You may qualify if:
- Provision of signed informed consent prior to any study specific procedures
- Female or male aged ≥18 years at the time of consent
- eGFR ≥25 and ≤75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1
- Evidence of increased albuminuria 3 months or more before visit 1 and UACR ≥200 and ≤5000 mg/g at visit 1
- Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated,
You may not qualify if:
- Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis
- Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment
- History of organ transplantation
- Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
- Type 1 diabetes mellitus
- New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment
- MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (390)
Research Site
Birmingham, Alabama, 35233, United States
Research Site
Hawaiian Gardens, California, 90716, United States
Research Site
Lomita, California, 90717, United States
Research Site
Los Angeles, California, 90022, United States
Research Site
Palo Alto, California, 94304, United States
Research Site
San Dimas, California, 91773, United States
Research Site
San Ramon, California, 94582, United States
Research Site
Vista, California, 92083, United States
Research Site
Aurora, Colorado, 80045, United States
Research Site
Denver, Colorado, 80246, United States
Research Site
Boynton Beach, Florida, 33435, United States
Research Site
Boynton Beach, Florida, 33472, United States
Research Site
Jacksonville, Florida, 32224, United States
Research Site
Miami, Florida, 33015, United States
Research Site
Miami, Florida, 33144, United States
Research Site
Miami, Florida, 33165, United States
Research Site
Miami Lakes, Florida, 33014, United States
Research Site
Naples, Florida, 34102, United States
Research Site
New Port Richey, Florida, 34652, United States
Research Site
Atlanta, Georgia, 30342-1797, United States
Research Site
Augusta, Georgia, 30904, United States
Research Site
Chicago, Illinois, 60643, United States
Research Site
Iowa City, Iowa, 52242, United States
Research Site
Topeka, Kansas, 66606, United States
Research Site
Wichita, Kansas, 67214, United States
Research Site
Metairie, Louisiana, 70006, United States
Research Site
Boston, Massachusetts, 02111, United States
Research Site
Detroit, Michigan, 48202, United States
Research Site
Flint, Michigan, 48504, United States
Research Site
Duluth, Minnesota, 55805, United States
Research Site
Omaha, Nebraska, 68105, United States
Research Site
Albany, New York, 12208, United States
Research Site
Asheville, North Carolina, 28801, United States
Research Site
Charlotte, North Carolina, 28207, United States
Research Site
Hickory, North Carolina, 28601, United States
Research Site
New Bern, North Carolina, 28562, United States
Research Site
Winston-Salem, North Carolina, 27103, United States
Research Site
Cincinnati, Ohio, 45219, United States
Research Site
Maumee, Ohio, 43537, United States
Research Site
Jersey Shore, Pennsylvania, 17740, United States
Research Site
Philadelphia, Pennsylvania, 19104, United States
Research Site
Greer, South Carolina, 29651, United States
Research Site
Kingsport, Tennessee, 37660, United States
Research Site
Nashville, Tennessee, 37232, United States
Research Site
El Paso, Texas, 79935, United States
Research Site
Fort Worth, Texas, 76116, United States
Research Site
Fort Worth, Texas, 76117, United States
Research Site
Fort Worth, Texas, 76164, United States
Research Site
Houston, Texas, 77004, United States
Research Site
Houston, Texas, 77030, United States
Research Site
Odessa, Texas, 79761, United States
Research Site
Burke, Virginia, 22015, United States
Research Site
Manassas, Virginia, 20110, United States
Research Site
Newport News, Virginia, 23606, United States
Research Site
Tacoma, Washington, 98405, United States
Research Site
Buenos Aires, ARG 1425, Argentina
Research Site
Buenos Aires, C1425BGN, Argentina
Research Site
Buenos Aires, C1429BWN, Argentina
Research Site
CABA, C1119ACN, Argentina
Research Site
CABA, C1120AAC, Argentina
Research Site
Ciudad Autonoma Buenos Aires, 1093, Argentina
Research Site
Ciudad Autonoma de Buenos Aire, C1407GTN, Argentina
Research Site
Corrientes, W3400AMZ, Argentina
Research Site
Córdoba, 5000, Argentina
Research Site
Córdoba, X5006CBI, Argentina
Research Site
Córdoba, X5016LIG, Argentina
Research Site
Mar del Plata, 7600, Argentina
Research Site
Mar del Plata, B7600FZN, Argentina
Research Site
Nueve de Julio, B6500EZL, Argentina
Research Site
Rosario, S2000DEJ, Argentina
Research Site
San Luis, D5700CTA, Argentina
Research Site
San Miguel de Tucumán, 4000, Argentina
Research Site
San Miguel de Tucumán, T4000ICL, Argentina
Research Site
San Nicolás, B2900DMH, Argentina
Research Site
Santa Fe, 3000, Argentina
Research Site
Santa Rosa, 6300, Argentina
Research Site
Botucatu, 18.618-686, Brazil
Research Site
Campinas, 13010-001, Brazil
Research Site
Caxias do Sul, 95070-560, Brazil
Research Site
Curitiba, 80440-020, Brazil
Research Site
Joinville, 89227-680, Brazil
Research Site
Porto Alegre, 90020-090, Brazil
Research Site
Porto Alegre, 90035-903, Brazil
Research Site
Porto Alegre, 90610-000, Brazil
Research Site
Salvador, 40415-065, Brazil
Research Site
Santo André, 09090-790, Brazil
Research Site
São José do Rio Preto, 15090-000, Brazil
Research Site
São Paulo, 01228-000, Brazil
Research Site
São Paulo, 04039-000, Brazil
Research Site
São Paulo, 05403-000, Brazil
Research Site
Edmonton, Alberta, T6H 2L4, Canada
Research Site
Red Deer, Alberta, T4N 6V7, Canada
Research Site
Vancouver, British Columbia, V6Z 1Y6, Canada
Research Site
Halifax, Nova Scotia, B3H 1V7, Canada
Research Site
Brampton, Ontario, L6S 0C6, Canada
Research Site
Concord, Ontario, L4K 4M2, Canada
Research Site
Etobicoke, Ontario, M9R 4E1, Canada
Research Site
Kingston, Ontario, K7L 2V7, Canada
Research Site
London, Ontario, N6A 5A5, Canada
Research Site
Oakville, Ontario, L6K 3V3, Canada
Research Site
Oshawa, Ontario, L1G 2B9, Canada
Research Site
Smiths Falls, Ontario, K7A 4W8, Canada
Research Site
Toronto, Ontario, M4C 5T2, Canada
Research Site
Toronto, Ontario, M5G 2N2, Canada
Research Site
Chicoutimi, Quebec, G7H 7K9, Canada
Research Site
Gatineau, Quebec, J8Y 6S8, Canada
Research Site
Greenfield Park, Quebec, J4V 2H1, Canada
Research Site
Montreal, Quebec, H1T 2M4, Canada
Research Site
Montreal, Quebec, H4J 1C5, Canada
Research Site
Pointe-Claire, Quebec, H9R 3J1, Canada
Research Site
Sherbrooke, Quebec, J1H 5N4, Canada
Research Site
Baotou, 14010, China
Research Site
Beijing, 100034, China
Research Site
Beijing, 100044, China
Research Site
Beijing, 102206, China
Research Site
Changchun, 130021, China
Research Site
Changchun, 130041, China
Research Site
Changsha, 410008, China
Research Site
Chengdu, 610041, China
Research Site
Chengdu, 610072, China
Research Site
Foshan, 528000, China
Research Site
Fuzhou, 350025, China
Research Site
Guangzhou, 510000, China
Research Site
Guangzhou, 510080, China
Research Site
Guangzhou, 510515, China
Research Site
Guiyang, 550004, China
Research Site
Jilin, 132000, China
Research Site
Lanzhou, 730030, China
Research Site
Nanchang, 330006, China
Research Site
Nanjin, 210029, China
Research Site
Nanjing, 210009, China
Research Site
Nanning, 530021, China
Research Site
Ningbo, 315010, China
Research Site
Shanghai, 200025, China
Research Site
Shanghai, 200040, China
Research Site
Shanghai, 200090, China
Research Site
Shanghai, 200127, China
Research Site
Shengyang, 110004, China
Research Site
Shenzhen, 518053, China
Research Site
Tianjin, 300052, China
Research Site
Wuhan, 430033, China
Research Site
Yinchuan, 750004, China
Research Site
Yueyang, 414000, China
Research Site
Aarhus, 8200, Denmark
Research Site
Gentofte Municipality, 2820, Denmark
Research Site
Herlev, 2730, Denmark
Research Site
Hillerød, 3400, Denmark
Research Site
København Ø, 2100, Denmark
Research Site
Roskilde, 4000, Denmark
Research Site
Aschaffenburg, 63739, Germany
Research Site
Bad Oeynhausen, 32545, Germany
Research Site
Berlin, 10117, Germany
Research Site
Dresden, 01307, Germany
Research Site
Düsseldorf, 40210, Germany
Research Site
Essen, 45136, Germany
Research Site
Frankfurt am Main, 60590, Germany
Research Site
Hanover, 30625, Germany
Research Site
Magdeburg, 39120, Germany
Research Site
München, 81675, Germany
Research Site
Münster, 48145, Germany
Research Site
Schweinfurt, 97421, Germany
Research Site
Tübingen, 72076, Germany
Research Site
Ulm, 89081, Germany
Research Site
Budapest, 1083, Hungary
Research Site
Budapest, 1096, Hungary
Research Site
Budapest, 1106, Hungary
Research Site
Budapest, 1212, Hungary
Research Site
Eger, 3300, Hungary
Research Site
Gyula, 5700, Hungary
Research Site
Kistarcsa, 2143, Hungary
Research Site
Miskolc, 3526, Hungary
Research Site
Nyíregyháza, 4400, Hungary
Research Site
Pécs, 7624, Hungary
Research Site
Szeged, 6720, Hungary
Research Site
Velence, 2481, Hungary
Research Site
Ahmedabad, 380016, India
Research Site
Bangalore, 560002, India
Research Site
Calicut, 673008, India
Research Site
Chennai, 600001, India
Research Site
Ernākulam, 683594, India
Research Site
Hyderabad, 500018, India
Research Site
Kanpur, 208002, India
Research Site
Kolkata, 700020, India
Research Site
Lucknow, 226003, India
Research Site
Lucknow, 226005, India
Research Site
Madurai, 625020, India
Research Site
Maharashtra, 411013, India
Research Site
Mangalore, 575003, India
Research Site
Nagpur, 440003, India
Research Site
Nagpur, 440012, India
Research Site
New Delhi, 110017, India
Research Site
Pune, 411001, India
Research Site
Pune, 411040, India
Research Site
Vijayawada, 522002, India
Research Site
Amagasaki-shi, 660-8550, Japan
Research Site
Asahikawa-shi, 070-8644, Japan
Research Site
Beppu-shi, 874-0011, Japan
Research Site
Bunkyō City, 113-8431, Japan
Research Site
Chiba, 260-8712, Japan
Research Site
Chūōku, 103-0002, Japan
Research Site
Chūōku, 103-0027, Japan
Research Site
Chūōku, 104-0031, Japan
Research Site
Daito-shi, 574-0074, Japan
Research Site
Fujisawa-shi, 251-8550, Japan
Research Site
Fukuoka, 810-0065, Japan
Research Site
Higashiibaraki-gun, 311-3193, Japan
Research Site
Iizuka-shi, 820-8505, Japan
Research Site
Itabashi-ku, 173-8610, Japan
Research Site
Kamakura-shi, 247-8533, Japan
Research Site
Kanazawa, 920-8650, Japan
Research Site
Kawachinagano-shi, 586-8521, Japan
Research Site
Kawasaki-shi, 211-8510, Japan
Research Site
Kobe, 654-0155, Japan
Research Site
Koga-shi, 811-3195, Japan
Research Site
Koshigaya-shi, 343-8577, Japan
Research Site
Kumamoto, 860-0008, Japan
Research Site
Kurashiki, 701 0192, Japan
Research Site
Matsumoto-shi, 390-8621, Japan
Research Site
Nagano, 388-8004, Japan
Research Site
Nagoya, 455-8530, Japan
Research Site
Nagoya, 456-0058, Japan
Research Site
Nagoya, 457-8511, Japan
Research Site
Naha, 902-0061, Japan
Research Site
Neyagawa, 572-0015, Japan
Research Site
Niigata, 951-8520, Japan
Research Site
Okayama, 700-8558, Japan
Research Site
Okayama, 701-1192, Japan
Research Site
Osaka, 530-8480, Japan
Research Site
Osaka, 540-0006, Japan
Research Site
Osaka, 558-8558, Japan
Research Site
Ōita, 870-0039, Japan
Research Site
Saga, 840-8571, Japan
Research Site
Sapporo, 063-0005, Japan
Research Site
Shizuoka, 420-8630, Japan
Research Site
Takarazuka-shi, 665-0861, Japan
Research Site
Toride-shi, 302-0022, Japan
Research Site
Tsu, 514-1101, Japan
Research Site
Tsu, 514-8507, Japan
Research Site
Tsuchiura-shi, 300-0028, Japan
Research Site
Ueda-shi, 386-8610, Japan
Research Site
Uji-shi, 611-0041, Japan
Research Site
Yaizu-shi, 425-8505, Japan
Research Site
Yokohama, 232-0024, Japan
Research Site
Aguascalientes, 20230, Mexico
Research Site
Cuernavaca, 62448, Mexico
Research Site
Culiacán, 80230, Mexico
Research Site
D.F, 14000, Mexico
Research Site
Durango, 34000, Mexico
Research Site
Guadalajara, 44600, Mexico
Research Site
Mazatlán, 82000, Mexico
Research Site
Mazatlán, 82110, Mexico
Research Site
México, 06700, Mexico
Research Site
México, 06726, Mexico
Research Site
México, 14080, Mexico
Research Site
Minatitlán, 96730, Mexico
Research Site
Monterrey, 64060, Mexico
Research Site
Monterrey, 64460, Mexico
Research Site
Saltillo, 25230, Mexico
Research Site
Arequipa, AREQUIPA01, Peru
Research Site
Callao, CALLAO 2, Peru
Research Site
Chorrillos, Lima 9, Peru
Research Site
Cusco, CUSCO 01, Peru
Research Site
Ica, Peru
Research Site
Lima, 14, Peru
Research Site
Lima, 36, Peru
Research Site
Lima, L27, Peru
Research Site
Lima, LIMA 01, Peru
Research Site
Lima, LIMA 1, Peru
Research Site
Lima, LIMA 27, Peru
Research Site
Lima, LIMA 31, Peru
Research Site
Piura, Peru
Research Site
San Isidro, Lima 27, Peru
Research Site
San Miguel, Lima 32, Peru
Research Site
Bacolod, 6100, Philippines
Research Site
Cebu, 6000, Philippines
Research Site
Cebu City, 6000, Philippines
Research Site
Dasmariñas, 4114, Philippines
Research Site
Davao City, PH-8000, Philippines
Research Site
Iloilo City, 5000, Philippines
Research Site
Makati City, 1218, Philippines
Research Site
Marikina City, 1800, Philippines
Research Site
Quezon City, 1101, Philippines
Research Site
Bielsko-Biala, 43-300, Poland
Research Site
Bochnia, 32-700, Poland
Research Site
Chorzów, 41-500, Poland
Research Site
Ciechanów, 06-400, Poland
Research Site
Katowice, 40-081, Poland
Research Site
Katowice, 40-648, Poland
Research Site
Krakow, 31-156, Poland
Research Site
Krakow, 31-530, Poland
Research Site
Legnica, 59-220, Poland
Research Site
Lodz, 92-213, Poland
Research Site
Olsztyn, 10-561, Poland
Research Site
Ostrowiec Świętokrzyski, 27-400, Poland
Research Site
Oława, 55-200, Poland
Research Site
Poznan, 60-821, Poland
Research Site
Ruda Śląska, 41-709, Poland
Research Site
Rzeszów, 35-055, Poland
Research Site
Szczecin, 70-111, Poland
Research Site
Tczew, 83-110, Poland
Research Site
Chelyabinsk, 454091, Russia
Research Site
Kazan', 420012, Russia
Research Site
Kemerovo, 650002, Russia
Research Site
Kemerovo, 650066, Russia
Research Site
Krasnoyarsk, 660062, Russia
Research Site
Moscow, 123995, Russia
Research Site
Omsk, 644112, Russia
Research Site
Perm, 614000, Russia
Research Site
Perm, 614068, Russia
Research Site
Rostov-on-Don, 344022, Russia
Research Site
Saint Petersburg, 194354, Russia
Research Site
Saint Petersburg, 196601, Russia
Research Site
Saint Petersburg, 199106, Russia
Research Site
Saratov, 410053, Russia
Research Site
Tver', 170036, Russia
Research Site
Ufa, 450071, Russia
Research Site
Vladikavkaz, 362007, Russia
Research Site
Volgograd, 400131, Russia
Research Site
Yaroslavl, 150062, Russia
Research Site
Yekaterinburg, 620039, Russia
Research Site
Ansan-si, 15355, South Korea
Research Site
Deagu, 41944, South Korea
Research Site
Goyang-si, 10380, South Korea
Research Site
Goyang-si, 10444, South Korea
Research Site
Gwangju, 61469, South Korea
Research Site
Jeonju, 54907, South Korea
Research Site
Seongnam-si, 13620, South Korea
Research Site
Seoul, 03080, South Korea
Research Site
Seoul, 03722, South Korea
Research Site
Seoul, 06273, South Korea
Research Site
Seoul, 06591, South Korea
Research Site
Seoul, 07061, South Korea
Research Site
Seoul, 07804, South Korea
Research Site
Seoul, 07985, South Korea
Research Site
Uijeongbu-si, 11765, South Korea
Research Site
Wŏnju, 26426, South Korea
Research Site
A Coruña, 15006, Spain
Research Site
Barcelona, 08003, Spain
Research Site
Barcelona, 08035, Spain
Research Site
Burela (Lugo), 27880, Spain
Research Site
L'Hospitalet de Llobregat, 08907, Spain
Research Site
Madrid, 28041, Spain
Research Site
Málaga, 29010, Spain
Research Site
Santiago de Compostela, 15706, Spain
Research Site
Seville, 41071, Spain
Research Site
Valencia, 46010, Spain
Research Site
Valencia, 46017, Spain
Research Site
Gothenburg, 413 45, Sweden
Research Site
Malmo, 205 02, Sweden
Research Site
Stockholm, 141 86, Sweden
Research Site
Stockholm, 182 88, Sweden
Research Site
Uppsala, 751 85, Sweden
Research Site
Cherkasy, 18009, Ukraine
Research Site
Chernivtsі, 58018, Ukraine
Research Site
Dnipro, 49005, Ukraine
Research Site
Dnipro, 49102, Ukraine
Research Site
Ivano-Frankivsk, 76008, Ukraine
Research Site
Ivano-Frankivsk, 76018, Ukraine
Research Site
Kharkiv Region, 61039, Ukraine
Research Site
Kharkiv Region, 61103, Ukraine
Research Site
Kharkiv Region, 61166, Ukraine
Research Site
Kyiv, 02091, Ukraine
Research Site
Kyiv, 02125, Ukraine
Research Site
Kyiv, 04053, Ukraine
Research Site
Kyiv, 4050, Ukraine
Research Site
Lutsk, 43005, Ukraine
Research Site
Odesa, 65025, Ukraine
Research Site
Poltava, 36011, Ukraine
Research Site
Rivne, 33027, Ukraine
Research Site
Ternopil, 46000, Ukraine
Research Site
Vinnytsia, 21001, Ukraine
Research Site
Vinnytsia, 21018, Ukraine
Research Site
Zaporizhzhia, 69600, Ukraine
Research Site
Cardiff, CF14 4XW, United Kingdom
Research Site
Glasgow, G51 4TF, United Kingdom
Research Site
Hull, HU3 2JZ, United Kingdom
Research Site
Kent, BR6 8ND, United Kingdom
Research Site
Leicester, LE5 4PW, United Kingdom
Research Site
London, E1 1BB, United Kingdom
Research Site
London, SE5 9RS, United Kingdom
Research Site
Salford, M6 8HD, United Kingdom
Research Site
Swansea, SA6 6NL, United Kingdom
Research Site
Biên Hòa, 810000, Vietnam
Research Site
Hanoi, 10000, Vietnam
Research Site
Ho Chi Minh City, 10000, Vietnam
Research Site
Ho Chi Minh City, 7000000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Ho Chi Minh City, 70000, Vietnam
Research Site
Ho Chi Minh City, 9000, Vietnam
Research Site
Hochiminh, 700000, Vietnam
Related Publications (32)
Heerspink HJL, Chertow GM, Rossing P, Correa-Rotter R, Sjostrom CD, Toto RD, Wheeler DC, Jongs N. Effects of Dapagliflozin on Progression of CKD According to Different Rates of Pretrial eGFR Loss. Clin J Am Soc Nephrol. 2025 Nov 1;20(11):1527-1535. doi: 10.2215/CJN.0000000810. Epub 2025 Sep 9.
PMID: 41128261DERIVEDBakker WM, Heerspink HJL, Jongs N, Correa-Rotter R, Rossing P, Toto RD, Wheeler DC, McMurray JJV, Langkilde AM, Gansevoort RT, Chertow GM, Vart P. Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD. J Am Soc Nephrol. 2026 Jan 1;37(1):101-109. doi: 10.1681/ASN.0000000776. Epub 2025 Jul 18.
PMID: 40679863DERIVEDOshima M, Buizen L, Jongs N, Levin A, Chertow GM, Wheeler DC, Heerspink HJL, Arnott C, Jardine MJ, Mahaffey KW, Pollock C, Herrington WG, Perkovic V, Neuen BL. Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials. Clin J Am Soc Nephrol. 2025 Jul 14;20(9):1206-1214. doi: 10.2215/CJN.0000000771.
PMID: 40658498DERIVEDJongs N, Gasparyan SB, Frison L, Schloemer P, Brinker M, Little DJ, Heerspink HJL. Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point. J Am Soc Nephrol. 2025 Dec 1;36(12):2421-2430. doi: 10.1681/ASN.0000000766. Epub 2025 Jun 17.
PMID: 40526444DERIVEDvan Mil D, Vart P, Chertow GM, Gansevoort RT, Rossing P, Toto RD, Correa-Rotter R, Langkilde AM, Sjostrom CD, Wheeler DC, Heerspink HJL. Baseline, Early Changes, and Residual Albuminuria: Post Hoc Analysis of a Randomized Clinical Trial of Dapagliflozin in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2024 Dec 1;19(12):1574-1584. doi: 10.2215/CJN.0000000000000550.
PMID: 39475817DERIVEDNatale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
PMID: 38770818DERIVEDZhang Z, Heerspink HJL, Chertow GM, Correa-Rotter R, Gasparrini A, Jongs N, Langkilde AM, McMurray JJV, Mistry MN, Rossing P, Toto RD, Vart P, Nitsch D, Wheeler DC, Caplin B. Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial. Lancet Planet Health. 2024 Apr;8(4):e225-e233. doi: 10.1016/S2542-5196(24)00026-3.
PMID: 38580424DERIVEDHeerspink HJL, Stack AG, Terkeltaub R, Jongs N, Inker LA, Bjursell M, Maklad N, Perl S, Eklund O, Rikte T, Sjostrom CD, Perkovic V; SAPPHIRE Investigators. Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial. J Am Soc Nephrol. 2024 May 1;35(5):594-606. doi: 10.1681/ASN.0000000000000326. Epub 2024 Feb 20.
PMID: 38564654DERIVEDKoshino A, Schechter M, Chertow GM, Vart P, Jongs N, Toto RD, Rossing P, Correa-Rotter R, McMurray JJV, Gorriz JL, Isidto R, Kashihara N, Langkilde AM, Wheeler DC, Heerspink HJL. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. NEJM Evid. 2023 Jun;2(6):EVIDoa2300049. doi: 10.1056/EVIDoa2300049. Epub 2023 May 19.
PMID: 38320128DERIVEDYu MK, Vart P, Jongs N, Correa-Rotter R, Rossing P, McMurray JJV, Hou FF, Douthat W, Khullar D, Langkilde AM, Wheeler DC, Heerspink HJL, Chertow GM. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex. J Gen Intern Med. 2024 May;39(6):921-930. doi: 10.1007/s11606-023-08397-9. Epub 2023 Dec 14.
PMID: 38097862DERIVEDFletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. J Am Soc Nephrol. 2023 Dec 1;34(12):1965-1975. doi: 10.1681/ASN.0000000000000248. Epub 2023 Oct 25.
PMID: 37876229DERIVEDHeerspink HJL, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, Karpefors M, Wheeler DC, Bakris G, Perkovic V, Nkulikiyinka R, Rossert J, Gasparyan SB. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023 Dec 1;34(12):2025-2038. doi: 10.1681/ASN.0000000000000243. Epub 2023 Oct 24.
PMID: 37872654DERIVEDChertow GM, Correa-Rotter R, Vart P, Jongs N, McMurray JJV, Rossing P, Langkilde AM, Sjostrom CD, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial. J Am Heart Assoc. 2023 May 2;12(9):e028739. doi: 10.1161/JAHA.122.028739. Epub 2023 Apr 29.
PMID: 37119064DERIVEDVart P, Jongs N, Wheeler DC, Heerspink HJL, Langkilde AM, Chertow GM. Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 Apr 3;6(4):e2310877. doi: 10.1001/jamanetworkopen.2023.10877.
PMID: 37103935DERIVEDWilligers BJA, Ouwens M, Briggs A, Heerspink HJL, Pollock C, Pecoits-Filho R, Tangri N, Kovesdy CP, Wheeler DC, Garcia Sanchez JJ. The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial. Adv Ther. 2023 Jun;40(6):2741-2751. doi: 10.1007/s12325-023-02503-3. Epub 2023 Apr 18.
PMID: 37071317DERIVEDSchechter M, Jongs N, Chertow GM, Mosenzon O, McMurray JJV, Correa-Rotter R, Rossing P, Langkilde AM, Sjostrom CD, Toto RD, Wheeler DC, Heerspink HJL. Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD. Ann Intern Med. 2023 Jan;176(1):59-66. doi: 10.7326/M22-2115. Epub 2022 Dec 6.
PMID: 36469914DERIVEDVart P, Vaduganathan M, Jongs N, Remuzzi G, Wheeler DC, Hou FF, McCausland F, Chertow GM, Heerspink HJL. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes. Clin J Am Soc Nephrol. 2022 Dec;17(12):1754-1762. doi: 10.2215/CJN.08900722. Epub 2022 Nov 22.
PMID: 36414316DERIVEDMcEwan P, Darlington O, Miller R, McMurray JJV, Wheeler DC, Heerspink HJL, Briggs A, Bergenheim K, Garcia Sanchez JJ. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022 Dec;17(12):1730-1741. doi: 10.2215/CJN.03790322. Epub 2022 Nov 2.
PMID: 36323444DERIVEDJongs N, Chertow GM, Greene T, McMurray JJV, Langkilde AM, Correa-Rotter R, Kashihara N, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators; Members of the DAPA-CKD Trial Committees and Investigators. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. J Am Soc Nephrol. 2022 Nov;33(11):2094-2107. doi: 10.1681/ASN.2022030306. Epub 2022 Aug 17.
PMID: 35977807DERIVEDVart P, Correa-Rotter R, Hou FF, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Douthat W, Escudero E, Isidto R, Khullar D, Bajaj HS, Wheeler DC, Heerspink HJL. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. Kidney Int Rep. 2022 Feb 2;7(4):699-707. doi: 10.1016/j.ekir.2022.01.1060. eCollection 2022 Apr.
PMID: 35497805DERIVEDWaijer SW, Vart P, Cherney DZI, Chertow GM, Jongs N, Langkilde AM, Mann JFE, Mosenzon O, McMurray JJV, Rossing P, Correa-Rotter R, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. 2022 Jul;65(7):1085-1097. doi: 10.1007/s00125-022-05694-6. Epub 2022 Apr 21.
PMID: 35445820DERIVEDHeerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Greene T; DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4.
PMID: 34619108DERIVEDJongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4.
PMID: 34619106DERIVEDMcMurray JJV, Wheeler DC, Stefansson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Hou FF, Rossing P, Sjostrom CD, Solomon SD, Toto RD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC Heart Fail. 2021 Nov;9(11):807-820. doi: 10.1016/j.jchf.2021.06.017. Epub 2021 Aug 23.
PMID: 34446370DERIVEDPersson F, Rossing P, Vart P, Chertow GM, Hou FF, Jongs N, McMurray JJV, Correa-Rotter R, Bajaj HS, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care. 2021 Aug;44(8):1894-1897. doi: 10.2337/dc21-0300. Epub 2021 Jun 28.
PMID: 34183431DERIVEDWheeler DC, Stefansson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjostrom CD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
PMID: 33338413DERIVEDMcMurray JJV, Wheeler DC, Stefansson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Greene T, Held C, Hou FF, Mann JFE, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation. 2021 Feb 2;143(5):438-448. doi: 10.1161/CIRCULATIONAHA.120.051675. Epub 2020 Nov 13.
PMID: 33186054DERIVEDHeerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
PMID: 32970396DERIVEDWheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Gorriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjostrom CD, Langkilde AM, Heerspink HJL. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234.
PMID: 32862232DERIVEDPiperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021 Jan;35(1):12-25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10.
PMID: 32778748DERIVEDSternlicht HK, Bakris GL. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 Jul;8(7):553-555. doi: 10.1016/S2213-8587(20)30185-6. No abstract available.
PMID: 32559465DERIVEDGonzalez DE, Foresto RD, Ribeiro AB. SGLT-2 inhibitors in diabetes: a focus on renoprotection. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s17-s24. doi: 10.1590/1806-9282.66.S1.17.
PMID: 31939531DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- AstraZeneca Clinical Study Information Center
- Organization
- AstraZeneca
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 26, 2017
First Posted
January 30, 2017
Study Start
February 2, 2017
Primary Completion
June 12, 2020
Study Completion
June 12, 2020
Last Updated
July 7, 2021
Results First Posted
July 7, 2021
Record last verified: 2021-06
Data Sharing
- IPD Sharing
- Will not share